![](/img/cover-not-exists.png)
Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
Skrzypski, Marcin, Szymanowska-Narloch, Amelia, Dziadziuszko, RafałVolume:
3
Year:
2017
Language:
english
Journal:
Współczesna Onkologia
DOI:
10.5114/wo.2017.70116
File:
PDF, 68 KB
english, 2017